MINERALYS THERAPEUTICS INC

Company Overview

Mineralys Therapeutics (MLYS) is a clinical-stage biotechnology company (Healthcare — Biotechnology; Pharmaceutical Products) developing lorundrostat for treatment-resistant and uncontrolled hypertension and related renal indications. Q2 2025 performance was characterized by continued clinical progress — pivotal Launch-HTN and Advance-HTN results published in NEJM and JAMA, positive Phase 2 Explore-CKD topline, ongoing Transform-HTN extension and initiation of Explore-OSA — while the company remains pre-revenue and reliant on equity financings. Cash, cash equivalents and investments were $324.9M at June 30, 2025, management states runway >12 months under the current plan, and key near-term catalysts include a pre-NDA meeting in Q4 2025 and Explore-OSA topline H1 2026.

Executive Compensation Practices

As a pre-commercial biotech, Mineralys’ G&A increases were driven in Q2/YTD 2025 by higher headcount, cash compensation and stock-based compensation, indicating a compensation mix tilted toward equity to conserve cash while aligning executives with long‑term value creation. Typical industry practice applies here: modest base salaries with significant equity grants (RSUs/options) and milestone- or event-driven bonuses tied to clinical readouts, regulatory milestones (pre-NDA/NDA/approval) and partnering/commercialization events. Management’s emphasis on pre-commercial activities and preparing an NDA suggests near-term increases in compensation for regulatory and commercial hires and additional equity incentives to retain talent through approval and launch. Given no product revenue, short-term cash bonuses are likely constrained and equity dilution is a primary lever for rewarding executives.

Insider Trading Considerations

Insider trading at Mineralys should be interpreted in the context of frequent equity financings (March 2025 public offering, ATM sales) and material clinical/regulatory catalysts; insider sales around financings are common and may reflect liquidity needs rather than loss of confidence. Watch for Form 4 filings and the establishment or execution of 10b5-1 plans, especially around high‑visibility milestones (NEJM/JAMA publications, pre‑NDA/NDA interactions, topline readouts) and following financing transactions that change insiders’ liquidity profiles. Regulatory blackout windows are likely around clinical data releases and FDA meetings — trades during these periods carry elevated legal and reputational risk — and milestone/royalty obligations to Mitsubishi Tanabe could create additional material events that insiders must disclose and avoid trading on.